



HISTOLOGICAL AND HISTOCHEMICAL STUDIES ON THE
EFFECT OF CYCLOPHOSPHAMIDE ON SOME LYMPHATIC ORGANS IN
THE WHITE MOUSE

THESIS

Presented For The Degree Of Ph.D
In Hystology

SUBMITTED BY

Essam El-Dien Abdallah Mohamed El Sady
B.M.C.Ch - M.Sc. Hystology



24559

HYSTOLOGY DEPARTMENT
FACULTY OF MEDICINE
UNIVERSITY OF AIN SHAMS

1987

6/1/87

ACKNOWLEDGEMENTS

I wish to express my gratitude to Professor S.M. Mousa, the Head of the Histology Department, Ain Shams University, Cairo for his invaluable advice and help and for recommending me to Professor Turk's Department. I am extremely grateful to Professor J.L. Turk for his encouragement and interest and also for giving me the opportunity to do this work in the Pathology and Immunology Department in the Royal College of Surgeons of England in London.

My special thanks go to Dr. Darien Parker for help and support and friendly suggestions. Many thanks go to Dr. L.W. Poulter, Immunology Department, Royal Free Hospital, London for his advice on practical work. I would like to thank Miss Margaret Jacques for her excellent technical assistance, Frances Schindler for helping me in the cutting and processing of histological sections and also Steve Geschmeissner for his help in photography.

I am indebted to Tony Antoniou, Don Healey, Naveeda Agha and Colin Butter whose collaborations I most enjoyed and for their practical help and friendly suggestions. Many thanks go to Panayotis Papasavva for looking after my experimental animals. I also express my gratitude to Kerstin Kercher for the translation of German references and to the rest of the immunopharmacology group, T. Hamied, D. Baker and J. Bull. Many thanks go to Mrs. Penny Hurford for her patience in typing this thesis.

Finally, I would like to thank the Egyptian Culture centre for financing this work.



TABLE OF CONTENTS

	Page No.
ACKNOWLEDGEMENTS	1
TABLE OF CONTENTS	2
ILLUSTRATIONS	6
LIST OF ABBREVIATIONS	15
AIMS OF THE PRESENT STUDY	16
INTRODUCTION AND REVIEW OF LITERATURE	
1. Cyclophosphamide	17
2. Monoclonal antibodies	20
3. Histology of thymus	22
4. Histology of the lymph node	25
5. Histology of the spleen	28
6. Histology of Peyer's patches	32
7. Lymphocytes	34
8. Cells of the mononuclear phagocyte series.	39
9. Mast cells	42
10. Histological effects of cyclophosphamide on the thymus	44
11. Histological effects of cyclophosphamide on the lymph nodes.	46
12. Histological effects of cyclophosphamide on the spleen.	48
13. Histological effects of cyclophosphamide on Peyer's patches.	50

	Page No.
14. Histological effects of cyclophosphamide on the haemopoetic cells and leucocytes.	51
15. Effect of cyclophosphamide on macrophages.	53
16. Effect of cyclophosphamide on mast cells.	54
17. Effect of cyclophosphamide on the antibody synthesis and level.	55
18. Effect of cyclophosphamide on delayed type hypersensitivity reactions.	58
19. Effect of cyclophosphamide on T-lymphocyte subsets.	59

MATERIALS AND METHODS

Animals	62
Treatment with cyclophosphamide	62
Preparation of tissues for histological stains.	63
Preparation of tissues for monoclonal staining.	63
Preparation of tissues for single cell suspensions.	64
Preparation of cell cytopsmis.	65
Monoclonal reagents	65
Methyl green pyronin method for DNA and RNA staining.	66
Gordon and Sweet method for reticulin fibres staining.	68
Toluidine blue method for mast cell staining.	70
Leishman stain for leucocyte staining.	71
Avidin biotin complex method for immunoperoxidase staining.	73
Indirect immunoperoxidase staining method.	74

	Page No.
Analysis of cells in the investigated areas of lymphoid tissues.	76
Analysis of cells in the cytopins.	76
Statistical analysis.	77

RESULTS

Effect of cyclophosphamide on the weight of animals.	78
Effect of cyclophosphamide on the weight of the thymus.	78
Description of sections of the normal thymus.	79
Effect of cyclophosphamide on the thymus.	79
Effect of cyclophosphamide on the weight of cervical lymph node	81
Effect of cyclophosphamide on the weight of mesenteric lymph node.	82
Description of sections of normal lymph node (cervical and mesenteric).	82
Effect of cyclophosphamide on cervical and mesenteric lymph nodes	84
Effect of cyclophosphamide on the weight of the spleen.	86
Description of the histology of the normal spleen.	86
Effect of cyclophosphamide treatment on the spleen.	87
Description of sections of normal Peyer's patches.	90
Effect of cyclophosphamide on Peyer's patches.	90
Description of thymus sections stained with a panel of monoclonal antibodies.	113
Effect of cyclophosphamide (100 mg/kg) on the thymus.	113

	Page No.
Description of sections of mesenteric lymph node stained with a panel of monoclonal antibodies.	114
Effect of cyclophosphamide (100 mg/kg) on the mesenteric lymph node.	115
Description of sections of spleen stained with a panel of monoclonal antibodies.	116
Effect of cyclophosphamide (100mg/kg) on spleen.	117
Description of sections of Peyer's patches stained with a panel of monoclonal antibodies.	118
Effect of cyclophosphamide (100 mg/kg) on Peyer's patches.	118
Experimental Results of cytopins.	144
1. Thymus	144
2. Mesenteric lymph node	145
3. Spleen.	146
 DISCUSSION	
Thymus	165
Lymph node	168
Spleen	172
Peyer's patches	176
SUMMARY	179
CONCLUSIONS	182
REFERENCES	183
ARABIC SUMMARY	

ILLUSTRATIONS

<u>A. Figures</u>	Page No.
1. Thymus Sections from normal rats	
(a) Stained with H & E (Figure 1)	98
(b) Stained with W3/13 monoclonal antibody (Figure 28)	124
(c) Stained with W3/25 monoclonal antibody (Figure 30)	125
(d) Stained with OX8 monoclonal antibody (Figure 31)	125
(e) Stained with CT7 monoclonal antibody (control section) (Figure 29)	124
2. Thymus sections, 3 days after treatment with CY (100 mg/kg body weight)	
(a) Stained with H & E (Figure 2)	98
(b) Stained with toluidine blue (Figure 5)	100
(c) Stained with OX8 monoclonal antibody (Figure 32)	126
(d) Stained with W3/25 monoclonal antibody (Figure 35)	127
3. Thymus sections, 7 days after treatment with CY (100 mg/kg body weight)	
(a) Stained with methyl green pylonin (Figure 4)	99
(b) Stained with W3/13 monoclonal antibody (Figure 34)	127
(c) Stained with OX8 monoclonal antibody (Figure 33)	126
4. Thymus sections, 7 days after treatment with CY (250 mg/kg body weight)	
(a) Stained with H & E (Figure 3)	99

5. Thymus cytopspins from normal rats.		
(a) Stained with W3/13 monoclonal antibody (Figure 66)	153	
(b) Stained with W3/25 monoclonal antibody (Figure 67)	153	
(c) Stained with OX8 monoclonal antibody (Figure 68)	154	
(d) Stained with CT7 monoclonal antibody (Figure 72)	156	
6. Thymus cytopspins, 3 days after treatment with CY (100 mg/kg body weight)		
(a) Stained with OX8 monoclonal antibody (Figure 69)	154	
7. Thymus cytopspins, 7 days after treatment with CY (100 mg/kg body weight)		
(a) Stained with OX8 monoclonal antibody (Figure 70)	155	
(b) Stained with OX4 monoclonal antibody (Figure 71)	155	
8. Lymph node sections from normal rats.		
(a) Stained with H & E (Cortex) (Figure 6)	101	
(b) Stained with H & E (Paracortex) (Figure 11)	103	
(c) Stained with silver (Figure 15)	105	
(d) Stained with W3/13 monoclonal antibody (Figure 36)	128	
(e) Stained with W3/25 monoclonal antibody (Figure 37)	128	
(f) Stained with OX8 monoclonal antibody (Figure 38)	129	
(g) Stained with OX4 monoclonal antibody (Cortex) (Figure 41)	131	
(h) Stained with OX4 monoclonal antibody (Medulla) (Figure 42)	131	

	Page No.
9. Lymph node sections, 3 days after treatment with CY. (100 mg/kg body weight)	
(a) Stained with H & E (Figure 7)	101
(b) Stained with toluidine blue (Figure 14)	105
(c) Stained with silver (Figure 16)	106
(d) Stained with OX8 monoclonal antibody (Figure 39)	129
(e) Stained with W3/25 monoclonal antibody (Figure 40)	130
(f) Stained with OX4 monoclonal antibody (Cortex) (Figure 43)	132
(g) Stained with OX4 monoclonal antibody (Medulla) (Figure 44)	132
10. Lymph node sections, 7 days after treatment with CY (100 mg/kg body weight)	
(a) Stained with H & E (Figure 8)	102
(b) Stained with methyl green pyronin (Figure 13)	104
11. Lymph node sections, 3 days after treatment with CY (250 mg/kg body weight)	
(a) Stained with H & E (Cortex) (Figure 9)	102
(b) Stained with H & E (Medulla) (Figure 10)	103
12. Lymph node sections, 21 days after treatment with a chronic daily dose of CY (5 mg/kg body weight)	
(a) Stained with H & E (Paracortex) (Figure 12)	104
13. Lymph node cytopspins from normal rats.	
(a) Stained with W3/13 monoclonal antibody (Figure 73)	157

14. Lymph node cytopspins, 3 days after treatment with CY (100 mg/kg body weight) (a) Stained with W3/13 monoclonal antibody (Figure 74)	157
15. Lymph node cytopspins, 7 days after treatment with CY (100 mg/kg body weight) (a) Stained with W3/13 monoclonal antibody (Figure 75) (b) Stained with W3/13 monoclonal antibody (Figure 76)	158 158
16. Lymph node cytopspins, 14 days after treatment with CY (100 mg/kg body weight) (a) Stained with OX8 monoclonal antibody (Figure 78) (b) Stained with W3/25 monoclonal antibody (Figure 79)	159 160
17. Lymph node cytopspins, 21 days after treatment with CY (100 mg/kg body weight) (a) Stained with W3/13 monoclonal antibody (Figure 77)	159
18. Spleen sections from normal rats. (a) Stained with H & E (Figure 17) (b) Stained with W3/13 monoclonal antibody (Figure 45) (c) Stained with W3/25 monoclonal antibody (Figure 46) (d) Stained with OX8 monoclonal antibody (Figure 47) (e) Stained with OX4 monoclonal antibody (Figure 48) (f) Stained with OX4 monoclonal antibody (Figure 49)	107 133 133 134 134 135

	Page No.
19. Spleen sections, 3 days after treatment with CY (100 mg/kg body weight)	
(a) Stained with H & E (Figure 18)	107
(b) Stained with W3/13 monoclonal antibody (Figure 50)	135
(c) Stained with OX8 monoclonal antibody (Figure 52)	136
(d) Stained with OX4 monoclonal antibody (Figure 55)	138
20. Spleen sections, 7 days after treatment with CY (100 mg/kg body weight)	
(a) Stained with W3/13 monoclonal antibody (Figure 51)	136
(b) Stained with OX8 monoclonal antibody (Figure 53)	137
(c) Stained with W3/25 monoclonal antibody (Figure 54)	137
(d) Stained with OX4 monoclonal antibody (Figure 56)	138
21. Spleen sections, 14 days after treatment with CY (100 mg/kg body weight)	
(a) Stained with H & E (Figure 20)	108
22. Spleen sections, 7 days after treatment with CY (250 mg/kg body weight)	
(a) Stained with H & E (Figure 19)	108
23. Spleen cytopspins from normal rats.	
(a) Stained with OX4 monoclonal antibody (Figure 30)	161
24. Spleen cytopspins, 3 days after treatment with CY (100 mg/kg body weight)	
(a) Stained with OX4 monoclonal antibody (Figure 31)	161

25. Spleen cytopspins, 7 days after treatment with CY (100 mg/kg body weight)		
(a) Stained with OX4 monoclonal antibody	(Figure 82)	162
26. Spleen cytopspins, 14 days after treatment with CY (100 mg/kg body weight)		
(a) Stained with OX4 monoclonal antibody	(Figure 83)	162
(b) Stained with OX3 monoclonal antibody	(Figure 85)	163
(c) Stained with W3/13 monoclonal antibody	(Figure 86)	164
27. Spleen cytopspins, 21 days after treatment with CY (100 mg/kg body weight)		
(a) Stained with OX4 monoclonal antibody	(Figure 84)	163
(b) Stained with W3/13 monoclonal antibody	(Figure 87)	164
28. Peyer's patches sections from normal rats.		
(a) Stained with H & E	(Figure 21)	109
(b) Stained with H & E (Intertollicular area)	(Figure 23)	110
(c) Stained with silver	(Figure 26)	112
(d) Stained with W3/13 monoclonal antibody	(Figure 57)	139
(e) Stained with W3/25 monoclonal antibody	(Figure 58)	139
(f) Stained with OX3 monoclonal antibody	(Figure 59)	140
(g) Stained with OX8 monoclonal antibody	(Figure 60)	140
(h) Stained with OX4 monoclonal antibody	(Figure 61)	141
(i) Stained with CT7 monoclonal antibody (Control section)		
(Figure 65)		143

	Page No.
29. Sections of Peyer's patches 3 days after treatment with CY (100 mg/kg body weight)	
(a) Stained with H & E (Figure 22)	109
(b) Stained with silver (Figure 27)	112
(c) Stained with W3/13 monoclonal antibody (Figure 62)	141
(d) Stained with OX6 monoclonal antibody (Figure 63)	142
30. Section of Peyer's patches, 7 days after treatment with CY (100 mg/kg body weight)	
(a) Stained with methyl green pyronin (Figure 25)	111
(b) Stained with OX4 monoclonal antibody (Figure 64)	142
31. Sections of Peyer's patches, 21 days after treatment with a chronic daily dose of CY (5 mg/kg body weight)	
(a) Stained with H & E (Interfollicular area) (Figure 24)	110

B. TABLES

	Page No.	Page No.
1. Weights ($\pm$ SEM) of animals after treatment with CY.		93
2. Weights ($\pm$ SEM) of thymuses after treatment with CY.		94
3. Weights ($\pm$ SEM) of cervical lymph nodes after treatment with CY.		95
4. Weights ($\pm$ SEM) of mesenteric lymph nodes after treatment with CY.		96
5. Weights ($\pm$ SEM) of spleens after treatment with CY.		97
6. Percentage ($\pm$ SEM) of lymphocyte staining with a panel of monoclonal antibodies in the thymus from rats treated with CY.		120
7. Percentage ($\pm$ SEM) of lymphocyte staining with a panel of monoclonal antibodies in the paracortical area of mesenteric lymph nodes from rats treated with CY.		121
8. Percentage ($\pm$ SEM) of lymphocyte staining with a panel of monoclonal antibodies in the periarteriolar area of spleens from rats treated with CY.		122
9. Percentage ($\pm$ SEM) of lymphocyte staining with a panel of monoclonal antibodies in the interfollicular area of Peyer's patches from rats treated with CY.		123
10. Percentage ($\pm$ SEM) of small lymphocytes stained with a panel of monoclonal antibodies in thymus from rats treated with CY.		147
11. Percentage ($\pm$ SEM) of large lymphocytes staining with a panel of monoclonal antibodies in thymus from rats treated with CY.		148
12. Percentage ($\pm$ SEM) of large lymphocytes in the thymus of rats treated with CY.		149